Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026
Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026
Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026
Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026
Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026

Related Experiment Video

Updated: Jun 7, 2026

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

20.9K

Waldenström macroglobulinaemia.

Irene M Ghobrial1, Morie A Gertz, Rafael Fonseca

  • 1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

The Lancet. Oncology
|November 7, 2003
PubMed
Summary
This summary is machine-generated.

Waldenström macroglobulinemia (WM) is an incurable lymphoid cancer. Understanding its biology, including genetic factors like chromosome 6 deletions, is key to developing better therapies for this IgM-producing cancer.

More Related Videos

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.4K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

Related Experiment Videos

Last Updated: Jun 7, 2026

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

20.9K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.4K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with a serum monoclonal immunoglobulin M (IgM).
  • WM can cause hyperviscosity syndrome and is currently incurable, necessitating a deeper understanding of its biology and natural history.
  • Genetic alterations, such as deletions on chromosome 6, are increasingly recognized in WM.

Purpose of the Study:

  • To review the current understanding of Waldenström macroglobulinemia (WM).
  • To summarize the pathogenesis, clinical and laboratory features, prognostic factors, and therapeutic options for WM.
  • To discuss the current knowledge and available therapies for WM.

Main Methods:

  • Literature review of WM pathogenesis, clinical features, and treatment.
  • Summary of recent findings on WM genetics, including chromosome 6 deletions.
  • Analysis of current therapeutic modalities and ongoing clinical trials.

Main Results:

  • WM is characterized by IgM production and lymphoplasmacytic expansion.
  • Half of WM patients have deletions in the long arm of chromosome 6.
  • Current treatments include alkylator agents, purine nucleoside analogues, and rituximab, with combination therapy under investigation.

Conclusions:

  • WM is a distinct pathological entity, not merely a clinical syndrome.
  • Further research into WM biology and genetics is crucial for improved treatment strategies.
  • Optimal initial therapy for WM is still under investigation, with clinical trials exploring combination approaches.